Nukariya N, Niitani H, Taguchi T, Furue H, Ota K, Tsukagoshi S, Ariyoshi Y, Ikeda M, Akasaka Y, Ohta J
Department of Internal Medicine IV, Nippon Medical School, Tokyo, Japan.
Gan To Kagaku Ryoho. 1992 Aug;19(9):1375-85.
Anti-emetic effects, safety and usefulness of Ondansetron given intravenously at 4 mg once daily for consecutive 3-5 days were investigated against nausea and emesis induced by non-platinum anticancer drugs. Efficacy rates in control of nausea and emesis were 59% (20/34 cases) and 68% (23/34 cases), respectively. The efficacy rate for inhibition of nausea and emesis, calculated based on the control of nausea and emesis, was 68% (23/34 cases). Adverse events (headache and constipation) were observed in 1 case and abnormal change in clinical laboratory findings (increase in eosinophil count) in another case. Out of 42 cases in which safety was evaluated, 41 (98%) cases were assessed as "no problem in safety." However, one case with side effect was assessed as a "Minor problem in safety." From the above, it was confirmed that Ondansetron injection exerted excellent inhibitory effects against nausea and emesis induced by non-platinum anti-cancer drugs, and this drug was a highly safe and useful anti-emetic.
研究了昂丹司琼连续3 - 5天每天静脉注射4毫克对非铂类抗癌药物引起的恶心和呕吐的止吐效果、安全性及有效性。恶心和呕吐的控制有效率分别为59%（20/34例）和68%（23/34例）。基于恶心和呕吐的控制计算的恶心和呕吐抑制有效率为68%（23/34例）。1例出现不良事件（头痛和便秘），另1例临床实验室检查结果出现异常变化（嗜酸性粒细胞计数增加）。在评估安全性的42例中，41例（98%）被评估为“安全性无问题”。然而，1例有副作用的病例被评估为“安全性有小问题”。由此证实，昂丹司琼注射液对非铂类抗癌药物引起的恶心和呕吐具有优异的抑制作用，该药物是一种高度安全且有效的止吐药。
